Author: López AB et al.
Citation: EMJ Hematol. 2026; https://doi.org/10.33590/emjhematol/7E8FP6Z1
Date correction published: 22/07/2026
Original publication¹
In the article1 published on the EMJ website on 16th July 2026, the following errors were present in Table 1.
In the ‘Suri et al. (2012)18’ row, several cells had been duplicated from the row below: those in the ‘Tumour type’, ‘Did PCD precede diagnosis?’, ‘Neurological outcome’, and Antibody persistence after treatment’ columns. The information inside these cells has now been updated.
Additionally, the table legend was missing:
- A footnote description, with the footnote present in the ‘Graus et al. (2014)2‘, ‘Reported anti-Tr cases (N)’ cell. This footnote description has now been added.
- The full list of acronyms with their meanings. This has now been added.
Original Table 1
Table 1: Summary of published reports on anti-Tr/DNER PCD associated with HL reviewed in the literature.1-3,6-19
PCD: paraneoplastic cerebellar degeneration; NR: not reported; vs: versus.
Updated Table 1
Table 1: Summary of published reports on anti-Tr/DNER PCD associated with HL reviewed in the literature.1-3,6-19
aGraus2 integrates data from the Bernal et al.3 and Hammack et al.15 series.
ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; CSF: cerebrospinal fluid; DFPP: double filtration plasmapheresis; DNER: delta/notch-like epidermal growth factor-related receptor; HL: Hodgkin lymphoma; IVIg: intravenous Ig; PCD: paraneoplastic cerebellar degeneration; NR: not reported; vs: versus.
EMJ apologises for the error and any inconvenience caused.
Reference:
1. López AB et al. Hodgkin lymphoma associated with paraneoplastic cerebellar degeneration with anti-Tr (DNER) antibodies: a case report. EMJ Hematol. 2026;14(1):69-76.
